Another trial comparing irreversible FGFR1–4 inhibitor, futibabinib, with gemcitabine-cisplatin as a first-line therapy for patients with advanced CCA bearing FGFR2 gene rearrangements (FOENIX-CCA3) also is in phase III [87]. Here, FGFR2 is linked to cholangiocarcinoma.